Treatment of Drug-induced Liver Injury in Valproate Hepatotoxicity

Valproate hepatotoxicity is a recognised and serious cause of drug-induced liver injury (DILI). Prompt identification and immediate management are essential — evidence indicates that timely intervention significantly affects survival outcomes.

This protocol is specific to liver injury arising in the context of valproate hepatotoxicity — a distinct sub-type of drug-induced liver injury where valproate is the causative agent. Studies in both animal models and humans support the existence of a specific antidote for this condition, making early recognition and action critical.

Management involves the prompt intravenous administration of a specific antidote agent — evidence supports that giving it early, particularly via the intravenous route, improves survival. The complete regimen, including administration schedule, is available in the full structured protocol below.